Printer Friendly

European Orphan Committee issues positive opinion for La Jolla's LJPC-401.

M2 EQUITYBITES-September 14, 2015-European Orphan Committee issues positive opinion for La Jolla's LJPC-401

(C)2015 M2 COMMUNICATIONS http://www.m2.com

La Jolla Pharmaceutical Company (Nasdaq: LJPC), a US-based pharmaceutical company, announced on Friday that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending LJPC-401, La Jolla's novel formulation of hepcidin, for designation as an orphan medicinal product for the treatment of chronic iron overload requiring chelation therapy.

Chronic iron overload occurs in patients suffering from beta thalassemia, sickle cell disease and hereditary hemochromatosis (HH). The final opinion, which is subject to review and approval by the European Commission (EC), may include all or a subset of these conditions.

Beta thalassemia and sickle cell disease are genetic diseases of blood cells that can cause life-threatening anaemia and often require frequent and life-long blood transfusions. These blood transfusions, while necessary to treat anaemia, cause excessive iron accumulation in the body, which is toxic to vital organs. HH is a disease caused by a genetic deficiency in hepcidin production, resulting in excessive iron accumulation. HH is the most common genetic disease in Caucasians and causes liver cirrhosis, liver cancer, heart disease and/or failure, dementia and diabetes.

Iron chelators are drugs that bind to and help clear excessive iron from the body. However, chelators cause significant toxicity, including kidney failure, liver failure or gastrointestinal haemorrhage. LJPC-401 is La Jolla's novel formulation of hepcidin, a naturally occurring peptide hormone that is the body's regulator of iron absorption and distribution. Hepcidin prevents excessive iron accumulation in organs, such as the liver and heart, where it can cause significant damage and even result in death.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 14, 2015
Words:288
Previous Article:DataPath releases next generation monitor for remote networks.
Next Article:Acacia Pharma plans London IPO.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters